SG11201701710SA - Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody - Google Patents
Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibodyInfo
- Publication number
- SG11201701710SA SG11201701710SA SG11201701710SA SG11201701710SA SG11201701710SA SG 11201701710S A SG11201701710S A SG 11201701710SA SG 11201701710S A SG11201701710S A SG 11201701710SA SG 11201701710S A SG11201701710S A SG 11201701710SA SG 11201701710S A SG11201701710S A SG 11201701710SA
- Authority
- SG
- Singapore
- Prior art keywords
- disorder
- disease
- treating
- methods
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462047463P | 2014-09-08 | 2014-09-08 | |
PCT/US2015/048812 WO2016040238A1 (en) | 2014-09-08 | 2015-09-08 | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701710SA true SG11201701710SA (en) | 2017-04-27 |
Family
ID=54150681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701710SA SG11201701710SA (en) | 2014-09-08 | 2015-09-08 | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160067336A1 (en) |
EP (1) | EP3191104A1 (en) |
JP (1) | JP2017526700A (en) |
KR (1) | KR20170045237A (en) |
CN (1) | CN106604745A (en) |
AU (1) | AU2015315435A1 (en) |
CA (1) | CA2960490A1 (en) |
EA (1) | EA201790543A1 (en) |
IL (1) | IL250887A0 (en) |
MX (1) | MX2017002875A (en) |
SG (1) | SG11201701710SA (en) |
WO (1) | WO2016040238A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6502959B2 (en) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | PD-1 antibodies, antigen binding fragments thereof and their medical use |
EP3808349B1 (en) | 2014-08-07 | 2022-10-05 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
MY194225A (en) * | 2015-03-13 | 2022-11-22 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US11078278B2 (en) * | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
WO2017161154A2 (en) * | 2016-03-16 | 2017-09-21 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Pd1 and pdl-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia |
SG11201810951RA (en) | 2016-06-10 | 2019-01-30 | Io Therapeutics Inc | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
WO2018007554A1 (en) * | 2016-07-06 | 2018-01-11 | Pierre Fabre Medicament | Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination |
CA3039451A1 (en) * | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
AU2017353427A1 (en) | 2016-11-02 | 2019-05-16 | Bristol-Myers Squibb Company | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
WO2018160717A1 (en) * | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
CA3060581A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
CN110914302A (en) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | Activatable anti-PDL 1 antibodies and methods of use thereof |
CN110996934A (en) | 2017-07-13 | 2020-04-10 | Io治疗公司 | Receptor subtype and function selective retinoid and REXINOID compounds for cancer immunotherapy in combination with immunomodulators |
CN111148514A (en) | 2017-08-31 | 2020-05-12 | Io治疗公司 | RAR selective agonists combined with immunomodulators for cancer immunotherapy |
WO2020102325A1 (en) * | 2018-11-13 | 2020-05-22 | Yee Amy | Compositions and methods of enhancing immunotherapies |
US20220143179A1 (en) * | 2019-03-04 | 2022-05-12 | North Carolina State University | Drug delivery for combination of epigenetic modulation and immune checkpoint blockade |
KR20210097882A (en) * | 2020-01-30 | 2021-08-10 | 삼성바이오에피스 주식회사 | Stable anti-PD-1 antibody pharmaceutical formulations |
EP4419075A1 (en) | 2021-10-19 | 2024-08-28 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR036993A1 (en) * | 2001-04-02 | 2004-10-20 | Wyeth Corp | USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS |
EP3133086B1 (en) * | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
US8492361B2 (en) * | 2009-02-10 | 2013-07-23 | Celgene Corporation | Methods for treating non-small cell lung cancer using 5-azacytidine |
US20130071403A1 (en) * | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
US20140357567A1 (en) * | 2011-11-01 | 2014-12-04 | Celgene Corporation | Methods for treating cancers using oral formulations of cytidine analogs |
EP2958571B1 (en) * | 2013-02-21 | 2024-04-10 | Michele Maio | Dna hypomethylating agents for cancer therapy |
WO2015035112A1 (en) * | 2013-09-05 | 2015-03-12 | The Johns Hopkins University | Cancer therapy via a combination of epigenetic modulation and immune modulation |
-
2015
- 2015-09-08 EA EA201790543A patent/EA201790543A1/en unknown
- 2015-09-08 EP EP15766985.4A patent/EP3191104A1/en not_active Withdrawn
- 2015-09-08 SG SG11201701710SA patent/SG11201701710SA/en unknown
- 2015-09-08 CN CN201580048157.4A patent/CN106604745A/en not_active Withdrawn
- 2015-09-08 WO PCT/US2015/048812 patent/WO2016040238A1/en active Application Filing
- 2015-09-08 US US14/847,570 patent/US20160067336A1/en not_active Abandoned
- 2015-09-08 MX MX2017002875A patent/MX2017002875A/en unknown
- 2015-09-08 AU AU2015315435A patent/AU2015315435A1/en not_active Abandoned
- 2015-09-08 JP JP2017513044A patent/JP2017526700A/en active Pending
- 2015-09-08 CA CA2960490A patent/CA2960490A1/en not_active Abandoned
- 2015-09-08 KR KR1020177006031A patent/KR20170045237A/en unknown
-
2017
- 2017-03-02 IL IL250887A patent/IL250887A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017526700A (en) | 2017-09-14 |
MX2017002875A (en) | 2017-05-30 |
CN106604745A (en) | 2017-04-26 |
AU2015315435A1 (en) | 2017-03-23 |
US20160067336A1 (en) | 2016-03-10 |
EA201790543A1 (en) | 2017-07-31 |
KR20170045237A (en) | 2017-04-26 |
IL250887A0 (en) | 2017-04-30 |
EP3191104A1 (en) | 2017-07-19 |
CA2960490A1 (en) | 2016-03-17 |
WO2016040238A1 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250887A0 (en) | Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody | |
HK1244293A1 (en) | Methods for tumor treatment using cd3xcd20 bispecific antibody | |
IL275092A (en) | Methods for treating crohn's disease using an anti-il23 antibody | |
IL247478A0 (en) | Bispecific her2 antibodies | |
IL246661B (en) | Human antibodies to pd-l1 | |
RS60030B1 (en) | Monoclonal antibodies against human b cell maturation antigen (bcma) | |
IL264502A (en) | Anti-cd3 antibody formulations | |
EP3174903C0 (en) | Bispecific single chain antibody construct with enhanced tissue distribution | |
IL285722B2 (en) | Dosage regimen of anti-amyloid beta monoclonal antibody for treating alzheimer's disease | |
IL252008A0 (en) | Methods for generating bispecific variable antibody domains and use thereof | |
SI3154583T1 (en) | Human monoclonal antibodies to ganglioside gd2 | |
HUE057708T2 (en) | Cells for producing human antibody | |
SG11201610594WA (en) | Anti-il4-il 13 bispecific antibodies | |
SG11201703292VA (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
IL272676B (en) | Anti-il4-il 13 bispecific antibodies | |
GB201600324D0 (en) | VPA medicine intermediate two methyl propyl cyanide synthesis method | |
GB201509493D0 (en) | Therapeutic antibody | |
GB201421735D0 (en) | Humanized gut microbiota |